A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations, or uncommon mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations, classical mutations, or uncommon mutations.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Apr 23, 2025 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Interventions being studied
- Drug: PLB1004
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Ability to understand and willingness to sign a written informed consent document; 2. Male or female adult patients 18 years of age or older; 3. Patients should have recovered from toxicities related to prior anti-tumor therapy; 4. Patients should have recovered from the effects of major surgery; 5. Have a documented EGFR mutation by a local test in tissue or plasma; 6. At least 12 weeks life expectancy; 7. Must have at least one measurable lesion per RECIST v 1.1; 8. Sexually active males and females of childbearing potential must agree to take effective contraceptive measures.
1. Received radiotherapy within 14 days before enrollment; 2. Have significant or uncontrolled systemic disease; 3. Have significant or uncontrolled cardiovascular disease; 4. Have had other diagnosed malignant diseases that required treatment within the past 3 years besides NSCLC; 5. Currently have or had a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia that requires steroid therapy; 6. Have known hypersensitivity to the similar drugs and excipients of PLB1004; 7. Pregnant or lactating women; 8. Have used other experimental drugs within 2 weeks prior to the first dose of PLB1004; 9. Have any condition or illness that could affect the compliance with the protocol.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California-DavisSacramento, California
- Research SiteLouisville, Kentucky
- Nebraska Cancer SpecialistsOmaha, Nebraska
- Research SiteNew York, New York
- Sarah Cannon Research InstituteNashville, Tennessee
- Swedish Health SciencesSeattle, Washington
- Research SiteSeattle, Washington
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 23, 2025. Always confirm current availability with the study team.